Patients must have had completed a course of prior adjuvant trastuzumab. If less than 12 months of trastuzumab had been given, at least 8 prior doses of weekly trastuzumab, or at least 3 prior doses of trastuzumab given every 3 weeks must have been administered. Also, it had to be specified that the patient was either not eligible or unable to receive further adjuvant trastuzumab, since the patient either 1) completed the intended treatment course of adjuvant trastuzumab-based on published data (FinHER regimen), or 2) experienced side effects that resulted in early discontinuation of trastuzumab that have since resolved.